HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer.

AbstractBACKGROUND:
Recent reports have suggested the efficacy of amrubicin (AMR) for relapsed small-cell lung cancer (SCLC). However, doses of AMR in these reports were 40 mg/m(2) or 45 mg/m(2), and severe and frequent myelosuppression were observed. Such side effects are occasionally intolerable, as serious myelosuppression may induce fatal infections. To overcome this clinical problem, we investigated whether 35 mg/m(2) of AMR administration with routine prophylactic use of granulocyte-colony stimulating factor (G-CSF) can reduce myelosuppression, while maintaining efficacy.
METHODS:
Between July 2003 and November 2008, 30 relapsed SCLC patients receiving 35 mg/m(2)/day of AMR were evaluated. Amrubicin was administered on days 1-3 every 3 or 4 weeks. Routine prophylactic use of G-CSF was performed beginning on day 8 and continuing for at least 5 consecutive days or until neutrophils recovered to the normal level.
RESULTS:
The median number of treatment cycles was four (range 1-9). No complete responses and 13 partial responses were observed, with response rates of: overall 43% (95% confidence interval [CI]: 26-63%); sensitive cases 33% (95% CI: 10-65%); and refractory cases 50% (95% CI: 26-74%) (p=0.4651). The disease control rate (partial response and stable disease) was 80% (95% CI: 61-92%). The progression-free survival times were: overall 4.2 months (95% CI: 3.2-5.2 months); sensitive cases 4.7 months (95% CI: 2.6-5.4 months); and refractory cases 3.5 months (95% CI: 2.6-5.2 months) (p=0.7124). The median OS times were: overall 9.6 months (95% CI: 7.2-12.5 months); sensitive cases 8.4 months (95% CI: 4.6-13.4 months); and refractory cases 11.0 months (95% CI: 6.5-12.6 months) (p=0.9315). The 1-year survival rate was 33%. Regarding grade 3/4 hematological toxicities: leukopenia (47%); neutropenia (50%); anemia (30%); and thrombocytopenia (33%) were observed. Febrile neutropenia occurred in three patients (10%). Transfusions of red blood cells and platelets were performed for eight (27%) and one (3%) patients, respectively. Treatment-related deaths and grade 3/4 non-hematological toxicities were not observed at all.
CONCLUSIONS:
Considering both safety and efficacy, AMR at a dose of 35 mg/m(2) with routine prophylactic use of G-CSF may be more desirable for the treatment of relapsed SCLC in clinical practice.
AuthorsAkito Hata, Nobuyuki Katakami, Shiro Fujita, Reiko Kaji, Shigeki Nanjo, Kyoko Otsuka, Yoko Kida, Yoichiro Higashi, Ryo Tachikawa, Michio Hayashi, Takashi Nishimura, Keisuke Tomii
JournalLung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 72 Issue 2 Pg. 224-8 (May 2011) ISSN: 1872-8332 [Electronic] Ireland
PMID20828862 (Publication Type: Journal Article)
CopyrightCopyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Anthracyclines
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • amrubicin
Topics
  • Aged
  • Anthracyclines (administration & dosage, adverse effects)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma, Small Cell (drug therapy, mortality, pathology, physiopathology)
  • Cell Count
  • Clinical Protocols
  • Disease-Free Survival
  • Female
  • Granulocyte Colony-Stimulating Factor (administration & dosage, adverse effects)
  • Humans
  • Leukopenia (etiology, prevention & control)
  • Lung Neoplasms (drug therapy, mortality, pathology, physiopathology)
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neutropenia (etiology, prevention & control)
  • Neutrophils (drug effects, pathology)
  • Recombinant Proteins
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: